Marker Therapeutics Inc (MRKR)

[hanscott]

So The Good, The Bad and The Ugly, as usual with any small biotech.

Our Chart since early March: mrkr.exe failed to load.

-------------------------------------

A. So the Pancreatic trial is delayed until next fall due to issues beyond our control(?):

1) FDA Hold, due to original manufacture's snafu, (?) and
2) Covid, which is delaying the response by the New manufacturer to the FDA-Hold on the reagent, and which is also causing the closure of the Mfg facilities at Baylor, which is our current source for production of "study drug supply."


And this is causing Enrollment to be Discontinued for now bc patients need to start Multi-TAA ~3mo after the start of chemo. So no reagents or Mfg facilities, no Multi-TAA T-Cell soup for you.

It is good to hear the team "remain optimistic that once we are able to open the study, there will be significant patient interest."



B. Phase 1, Arm A: Yaaay, FULL ENROLLMENT (sorta).
"Expect full enrollment (15 patients) by end of year"- by Jan 2020 ( see Dec 3 Piper Jaffray conference). This was the goal for the original Group A cohort in the original Phase 1, Filing.


Time fliess, I've gotta go so I'm leaving these links here for later:


ASCO May 29, 2020 PR for Presentation:
https://www.markertherapeutics.com/2020/05/marker-therapeutics-reports-interim-results-of-its-multitaa-specific-t-cell-therapy-in-patients-with-pancreatic-adenocarcinoma-at-the-2020-american-society-of-clinical-oncology-asco-virtual-annual-m/?utm_source=getresponse&utm_medium=email&utm_campaign=investor_alerts&utm_content=%5B%5Brssitem_title%5D%5D

---------

ASCO May 29, 2020 Poster Presentation:
https://www.markertherapeutics.com/wp-content/uploads/2020/05/TACTOPS-poster-2020-ASCO.pdf

-----------------

Q1 2020 CC:
https://seekingalpha.com/article/4346342-marker-therapeutics-inc-mrkr-ceo-peter-hoang-on-q1-2020-results-earnings-call-transcript?utm_medium=email&utm_source=seeking_alpha&mail_subject=mrkr-marker-therapeutics-inc-mrkr-ceo-peter-hoang-on-q1-2020-results-earnings-call-transcript&utm_campaign=rta-stock-article&utm_content=link-2

-----------------

Dec 3, 2019 Piper Jaffray Med Conference - my post with notes and link.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=153200625


-----------------
MRKR Original July 17, 2019 Pancreatic Cancer Data - PDF:https://www.markertherapeutics.com/wp-content/uploads/2019/07/TACTOPS-Investor-Presentation-FINAL-7-21-19-PDF.pdf )